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From October 31th – November 2nd, 2014, the 6th NEUROWIND e.V. meeting was held in Motzen, Brandenburg,
Germany. 70 doctoral students and postdocs from over 25 different groups working in German and Swiss university
hospitals or research institutes attended the meeting to discuss their latest experiments and findings in the fields of
neuroimmunology, neurodegeneration and neurovascular research. The meeting was regarded as a very well
organized platform to support research of young investigators in Germany and all participants enjoyed the
stimulating environment for lively in depth discussions.
According to the major aim of NEUROWIND e.V. to support younger researchers in Germany the 4th NEUROWIND
YOUNG SCIENTIST AWARD for experimental neurology was awarded to Michael Breckwoldt on his work in the group
of Thomas Misgeld (Institute of Neuronal Cell Biology, Technische Universität München, Germany). The successful
project was published in Nature Medicine entitled “Multiparametric optical analysis of mitochondrial redox signals
during neuronal physiology and pathology in vivo”. This outstanding paper deals with a molecular imaging approach
in living mice to optically analyze the role of mitochondrial redox signals in axons in health and disease. The award is
endowed with 20.000 Euro sponsored by Merck Serono GmbH, Darmstadt, Germany (unrestricted educational grant).
This year’s keynote lecture was given by Bernhard Hemmer, Head of the Department of Neurology at the Klinikum
rechts der Isar, Technische Universität München. Dr. Hemmer highlighted the particular role of B cells and (auto)
antibodies in multiple sclerosis (MS). As a new highlight Dr. Urbahns, head of global discovery technologies at Merck
research laboratories, gave insights from research practice in the pharmaceutical industry and introduced a shift in the
view on present-day drug discovery paradigms.* Correspondence:
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Contributions on vascular neurology
Kathrin Schüller from Nikolaus Plesnila’s group in Munich
focused on a mouse model of subarachnoid hemorrhage
demonstrating early microcirculatory dysfunction (e.g.
changes in vessel diameter, blood flow velocity). Next,
Robert Brunkhorst from the group of Waltraud Pfeilschifter,
Frankfurt, gave a talk on neuroregenerative effects of
selective serotonin reuptake inhibitors (SSRI) and the
sphingolipid-metabolism after induction of photothrombotic
stroke. Arthur Liesz from Munich studied the release of
alarmins also called DAMPs (danger-associated molecular
pattern) following MCAO. In mice and men a stroke-size
dependent up-regulation of high-motility group protein 1
(HMGB1) could be shown, although it has to be taken into
account that signals differ in the subacute and the chronic
phases after stroke induction. Christoph Harms from Berlin
discussed pros and cons of preclinical stroke models and
highlighted potential roadblocks in translational stroke re-
search. He pointed out that SUMO2/3 (small ubiquitin-like
modifier proteins) and their regulation by SENP7 (sentrin
specific peptidase 7) might contribute to endogenous
neuroprotection.
Hagen Huttner from Erlangen reported on the radiocar-
bon method as an innovative strategy to investigate adult
neurogenesis in the human brain, e.g. in stroke. The data
clearly show that after cortical infarction, there is no gener-
ation of new neurons in the brain. Kai Diederich from the
group of Jens Minnerup, Münster, studied the role of lym-
phocytes for regeneration in a long-term photothrombosis
model of cerebral ischemia. Thorsten Doeppner from Dirk
Herrmann’s group in Essen critically discussed the value of
neuronal stem cells and exosomes as neuroregenerative
approach in cerebral ischemia. Finally, Stine Mencl from
Christoph Kleinschnitz’s group reported on paradigms of
neuroprotection in stroke models using NMDAR activated
NOS molecules as targets of potential neuroprotective
approaches. Blocking the NOS pathway and thus reducing
toxic NO production appeared promising for protecting
neuronal tissue after stroke. Three inhibitors Tat-NR2B9c,
Tat-N-Dimer, and ZL006 were tested in the transient and
permanent MCAO paradigm in mice and rats. In contrast
to what was reported in the literature, no beneficial effect of
any of the NOS pathway inhibiting compounds was de-
tected. This reinvigorates the upcoming discussion on the
role of preclinical stroke models for testing neuroprotective
compounds to be used in human stroke patients.
Neuroimmunology and oligodendroglial biology
Johannes Herkel from Hamburg gave a talk on tolerance-
inducing liver cells controlling distinct stages of inflamma-
tion, e.g. in EAE animals. His group used nanoparticles as
carrier structures to deliver antigens to liver endothelialcells. The concept is translated to humans by initiation of
a clinical phase I trial. Next, Markus Kleinewietfeld,
Dresden, reported on the role of NaCl in autoimmunity
balancing regulatory T cell (Treg) and Th17 cell numbers
via the p38/MAP kinase pathway and serum- and
glucocorticoid-inducible kinase 1 (SGK1). These data
indicate a role of dietary habits as environmental factor to
modulate autoimmunity most likely via the gut micro-
biota. Jana Sonner from the group of Michael Platten in
Heidelberg gave a presentation on the role of tryptophan
catabolites on the development of Tregs and Th17 cells. A
particularly important role of the serine/threonine-protein
kinase general control non-derepressible 2 (GCN2) could be
shown. Karin Steinbach from the group of Doron Merkler,
Geneva, talked about viral footprints in the CNS and their
role as a trigger of autoimmunity (fertile field hypothesis).
Using the LCMV (non-cytolytic lymphocytic choriomenin-
gitis virus) infection mouse model the group could show
that preceeding infection of the brain early in life results in
“purged” glial cells that appear to support a higher lesion
load following EAE induction.
Next, Alexander Schulz from Jena (research group of
Helen Morrison) gave a presentation on neurofibroma-
tosis type II. Merlin, the gene product of NF2, interacts
with neuregulin 1, has a strong impact on the myelin
sheath, and influences axon structure maintenance.
Stefanie Jörg from Ralf Linker’s lab in Erlangen investi-
gated the role of dietary fatty acids and their impact on
CNS autoimmunity via the small intestine. The main out-
come of the study indicated a differential shift in Th17 and
Th1 cell numbers in the gut induced by lauric acid accom-
panied by an upregulation in IL17 and IFNg production.
In contrast, proprionic acid treatment resulted in upregu-
lated numbers of regulatory T cells associated with an
ameliorated disease course in EAE mice.
Marie Wunsch from Stefanie Kuerten’s group in
Würzburg presented data on the enteric nervous system as
a putative immune target in multiple sclerosis. Focusing on
NKG2D, Tobias Ruck from the group of Heinz Wiendl/Sven
Meuth (Münster) provided insights in the role of this recep-
tor on T cells in the EAE model as well as in patients suffer-
ing from MS or polymyositis. Vivien Thom from the group
of Tim Magnus gave a talk on interleukin-17 producing T
cells from the CSF as a possible marker for cerebral
vasculitis. Christina Ruland from Judith Alferink’s group in
Münster talked about tetraspanin-2 as a new murine tetra-
spanin in peripheral immune cells including neutrophils,
CD4 positive T cells, and conventional dendritic cells as well
as oligodendrocytes. Lena Krzyzak from Alexander Steinkas-
serer’s group in Erlangen focused on the role CD83 in the
immune response. Membrane bound C83 is present in
thymic epithelial cells, dendritic cells, and regulatory T cells
exerting different functions. In contrast soluble CD83 has
an immunmodulatory role via modulation of IDO.
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Paul Lingor from Göttingen reported on Rho kinase
(ROCK) inhibition as a therapeutic target for Amyo-
trophic Lateral Sclerosis (ALS) and Parkinson’s disease
(PD). ROCK inhibition by Fasudil was able to improve
functional outcome, reduce astrogliosis and increase num-
bers of microglial cells in a mouse model of amyotrophic
lateral sclerosis (SOD1G93A mice) and showed neuropro-
tection in PD models.
In a project by Markus Krohn from Magdeburg (group of
Jens Pahnke), APPPS1 mice were crossed onto FvB or
C57BL/6 backgrounds. Notably, the Ab42 peptide load in
the CNS of FVB mice was significantly lower than in the
C57BL/6 strain. Conversely, the extent of microglia activa-
tion was higher in the FVB background suggesting that
more active microglia in FVB mice were responsible for the
reduced plaque size in FVB mice. An interesting breeding
approach revealed that the differential microglia activation
between the strains might be due to mitochondrial differ-
ences in the microglia.
Ria Uhlemann from Mathias Endres’ group described
how NO release by microglia is modified by a post-
transcriptional mechanism involving the actin cytoskel-
eton. Actin filament stabilization in M1 polarised
microglia led to reduced NO production and reduced
TNF and IL-6 but increased IL-1b release. Similar
results were observed in Gelsolin KO mice. These
observations highlight the role for exocytotic pathways
in microglial cells as potential targets of interventional
strategies in conditions with chronic microglia activation.
Finally, Teja Groemer from the psychiatry department
of Erlangen presented new observations on presynaptic
APP trafficking. Cleaved APP products, Ab40 and Ab42,
are important biomarkers for neurodegenerative dis-
eases, in particular Alzheimer’s disease. APP is not part
of synaptic vesicles although its secretion is modulated
by synaptic activity. In fact, BACE and APP are sorted
away from synaptic vesicles in the presynaptic buton
and the “branching points” of these vesicle trafficking
pathways are under active investigation.
In conclusion, this year’s NEUROWIND meeting once
again proved to be an exciting platform for bringing
together highly motivated young scientists in experimental
neurology to discuss scientific progress in the fields of
neuroimmunology, vascular biology, and neurodegeneration.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RL, TM, TK, CK and SGM wrote the paper. All authors read and approved the
final manuscript.
Authors’ information
List of speakers at the 6’th scientific meeting of NEUROWIND e.V. (in alphabetical
order).Michael Breckwoldt, Universitätsklinik Heidelberg, Im Neuenheimer Feld 400,
69120 Heidelberg, Germany.
Robert Brunkhorst, Klinik für Neurologie, Universitätsklinikum der Goethe-Universität
Frankfurt, Schleusenweg 2–16, 60528 Frankfurt am Main, Germany.
Kai Diederich, Klinik für Allgemeine Neurologie, Universitätsklinikum Münster,
Albert-Schweitzer-Campus1, Gebäude A1, 48149 Münster, Germany.
Thorsten Doeppner, Department of Neurology, University of Duisburg-Essen,
45147 Essen, Germany.
Teja Groemer, Psychiatrische und Psychotherapeutische Klinik,
Schwabachanlage 6, 91054 Erlangen, Germany.
Christoph Harms, Abteilung für Experimentelle Neurologie, Centrum für
Schlaganfallforschung, Charité-Universitätsmedizin Berlin, Charitéplatz 1,
10117 Berlin.
Bernhard Hemmer, Neurologische Klinik und Poliklinik im Neuro-Kopf-
Zentrum, Klinikum rechts der Isar der Technischen Universität München,
Ismaninger Str. 22, 81675 München, Germany.
Johannes Herkel, I. Medizinische Klinik, Universitätsklinikum Hamburg-
Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Hagen Huttner, Department of Neurology, University of Erlangen-Nuremberg,
Schwabachanlage 6, 91054 Erlangen, Germany.
Stefanie Jörg, Neurologische Klinik, Universitätsklinikum Erlangen,
Schwabachanlage 6, 91054 Erlangen, Germany.
Markus Kleinewietfeld, Translational Immunology, Department of Clinical
Pathobiochemistry, Medical Faculty Carl Gustav Carus, TU Dresden,
Fetscherstraße 74, 01307 Dresden, Germany & Department of Neurology,
Yale School of Medicine, New Haven, 300 George St, CT 06511, USA.
Markus Krohn, Universität Magdeburg, Pahnke-Lab, Leipziger Str. 44, Haus 64,
39120 Magdeburg, Germany.
Lena Krzyzak, Department of Immune Modulation at the Department of
Dermatology, University Hospital Erlangen, Hartmannstraße 14, 91052
Erlangen, Germany.
Arthur Liesz, Institut für Schlaganfall- und Demenzforschung, Klinikum der
Universität München, Max-Lebsche-Platz 30, 81377 München, Germany.
Paul Lingor, Klinik für Neurologie, Universitätsmedizin Göttingen, Robert-
Koch-Str. 40, 37075 Göttingen, Germany.
Stine Mencl, Neurologische Klinik und Poliklinik, Universitätsklinikum
Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany.
Tobias Ruck, Klinik für Allgemeine Neurologie, Universitätsklinikum Münster,
Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster, Germany.
Christina Ruland, Department of Psychiatry, University Hospital Münster,
Albert-Schweitzer-Campus 1, Geb. A9, 48149 Münster, Germany.
Kathrin Schüller, Experimental Stroke Research, Institute for Stroke and
Dementia Research (ISD), University of Munich Medical School - Campus
Großhadern, Max-Lebsche Platz 30, 81377 Munich, Germany.
Alexander Schulz, Hans-Berger-Klinik für Neurologie, Universitätsklinikum
Jena, Erlanger Allee 101, 07743 Jena, Germany.
Jana Sonner, CCU Neuroimmunology and Brain Tumor Immunology (G160),
German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120
Heidelberg, Germany.
Karin Steinbach, Division of Clinical Pathology, Geneva University Hospital,
Department of Pathology and Immunology, Geneva Faculty of Medicine,
Centre Médical Universitaire, 1, rue Michel Servet, 1211 Geneva, Switzerland.
Vivien Thom, Institute of Immunology, University Medical Center Hamburg-
Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Ria Uhlemann, Klinik und Hochschulambulanz für Neurologie, Abteilung für
experimentelle Neurologie, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117
Berlin, Germany.
Klaus Urbahns, Discovery Technologies, Merck KGaA, Frankfurter Str. 250,
64293 Darmstadt, Germany.
Marie Wunsch, Institut für Anatomie und Zellbiologie I, AG
Neuroimmunologie, Universität Würzburg, Koellikerstraße 6, 97070 Würzburg,
Germany.
Acknowledgement
The NEUROWIND e.V. scientific meeting was kindly supported by Merck
Serono GmbH, Darmstadt, Germany (unrestricted grant to NEUROWIND e.V.).
This publication was funded by the German Research Foundation (DFG) in
the funding program Open Access Publishing.
Received: 17 December 2014 Accepted: 18 December 2014
